Anti-T Cell Antibodies as Part of the Preparative Regimen in Hematopoietic Cell Transplantation-A Debate

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 1 SUPPL., 2012, Pages

  Appelbaum, Frederick R ^a   Bacigalupo, Andrea ^b   Soiffer, Robert ^c  

^a USA   (United States)

^b UNIVERSITY OF GENOA   (Italy)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; METHOTREXATE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ARTICLE; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; DOSE RESPONSE; DRUG EFFICACY; HEMATOPOIETIC STEM CELL; HUMAN; MYELOID LEUKEMIA; NONHUMAN;

ANTILYMPHOCYTE SERUM; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOCYTE DEPLETION; PREOPERATIVE CARE; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 84855410526     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.11.002     Document Type: Article

References (15)

1. Bacigalupo A. Antithymocyte globulin for prevention of graft-versus-host disease. Curr Opin Hematol 2005, 12:457-462.
2. Kroger N., Zabelina T., Kruger W., et al. Invivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors. Bone Marrow Transplant 2002, 29:683-689.
3. Duggan P., Booth K., Chaudhry A., et al. Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT: a matched pair analysis. Bone Marrow Transplant 2002, 30:681-686.
4. Ramsay N.K.C., Kersey J.H., Robison L.L., et al. A randomized study of the prevention of acute graft-versus-host disease. NEngl J Med 1982, 306:392-397.
5. Bacigalupo A., Lamparelli T., Bruzzi P., et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001, 98:2942-2947.
6. Weiden P.L., Doney K., Storb R., Thomas E.D. Antihuman thymocyte globulin for prophylaxis of graft-versus-host disease. Arandomized trial in patients with leukemia treated with HLA-identical sibling marrow grafts. Transplantation 1979, 27:227-230.
7. Finke J., Bethge W.A., Schmoor C., et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009, 10:855-864.
8. Bacigalupo A., Lamparelli T., Barisione G., et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: Long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006, 12:560-565.
9. Socié G., Schmoor C., Bethge W.A., et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood 2011, 117:6375-6382.
10. Pavletic S.Z., Carter S.L., Kernan N.A., et al. Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. Blood 2005, 106:3308-3313.
11. Mohty M., Labopin M., Balère M.L., et al. Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Sociéte Française de Greffe de Moelle et de Thérapie Cellulaire. Leukemia 2010, 24:1867-1874.
12. Hamadani M., Blum W., Phillips G., et al. Improved nonrelapse mortality and infection rate with lower dose antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematological malignancies. Biol Blood and Marrow Transplant 2009, 15:1422-1430.
13. Johnston L. Acute graft-versus-host disease: differing risk with differing graft sources and conditioning intensity. Best Pract Res Clin Haematol 2008, 21:177-192.
14. Soiffer R.J., Lerademacher J., Ho V., et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 2011, 117:6963-6970.
15. Scheinberg P., Nunez O., Weinstein B., et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med 2011, 365:430-438.